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Joseph Pidala,1,3 Jongphil Kim,2,3 Mohamed A. Kharfan-Dabaja,1,3 Taiga Nishihori,1,3
Teresa Field,1,3 Janelle Perkins,1,3 Lia Perez,1,3 Hugo Fernandez,1,3 Claudio Anasetti1,3Disordered glucose metabolism is a common complication of glucocorticoid therapy for acute graft-versus-
host disease (aGVHD) after allogeneic hematopoietic cell transplantation (HCT). We aimed to examine the
impact of dysglycemia on outcomes in 173 recipients of HCT treated with glucocorticoids for aGVHD. A
total of 147 of these patients contributed data to a landmark analysis performed at 12 weeks post-HCT.
Median aGVHD onset was 21 days (range: 5-79) after transplant. Median duration of glucocorticoid therapy
was 381 days (range: 15-1632). Glucose values were obtained from glucocorticoid initiation date to death or
last follow-up, resulting in 11,588 total values. The median (range) for each parameter were: maximum 292
mg/dL (128-694), minimum 75mg/dL (34-142), average 142mg/dL (86-327), and standard deviation 46mg/dL
(12-108). Baseline diabetes mellitus predicted significantly greater maximum, mean, and standard deviation.
With median follow-up of 20 months (range: 3-55), median overall survival (OS) was 33.7 months (95% con-
fidence interval [CI] 16.4dnot reached). Onmultivariable analysis, maximum, average, or standard deviation
of glucose values predicted OS and maximum or average glucose values predicted nonrelapse mortality
(NRM). Minimum glucose values of (0-60 mg/dL) were associated with worsened OS and increased NRM.
Those patients treated with insulin or oral agents suffered significantly worse OS and increased NRM com-
pared to patients who did not need therapy. Finally, those with sustained maximum values .200 mg/dL
despite treatment suffered worse OS and increased NRM. These data suggest an independent adverse effect
of dysglycemia in patients treated with glucocorticoids for aGVHD, and argue for stringent glycemic control
in this setting.
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Acute graft-versus-host disease (aGVHD) is an im-
portant complication of allogeneic hematopoietic cell
transplantation (HCT) [1-5]. As the accepted initial
therapy for aGVHD, high-dose glucocorticoid ther-
apy provides a disappointing complete response rate
of 30% to 40% and engenders a burden of seriousDepartment of Blood andMarrowTransplantation; 2Bio-
ics, Moffitt Cancer Center; and 3Oncological Sciences,
rsity of Sough Florida, Tampa, Florida.
isclosure: See Acknowledgments on page 247.
dence and reprint requests: Joseph Pidala, MD, MS,
tments of Blood and Marrow Transplantation, Moffit
r Center, 12902 Magnolia Drive, MCC-GME, Tampa,
612-9416 (e-mail: joseph.pidala@moffitt.org).
arch 3, 2010; accepted July 4, 2010
erican Society for Blood and Marrow Transplantation
/$36.00
6/j.bbmt.2010.07.005adverse effects including steroid-induced hyperglyce-
mia, hypertension, fluid retention, cataracts, steroid
myopathy and deconditioning, osteopenia, and oppor-
tunistic infections [6-10]. The management of
aGVHD and later chronic graft-versus-host disease
(cGHVD) often results in prolonged treatment with
glucocorticoids [11]. In clinical practice, steroid-
induced hyperglycemia is a common and often
inadequately controlled complication.
In the setting of acute illness, stress hormones,
including cortisol and epinephrine, induce hyper-
glycemia.
Hyperglycemia is also induced by exogenous gluco-
corticoids. Importantly, hyperglycemia has adverse ef-
fects on several critical physiologic functions, leading to
decreased immune function [12,13], impaired wound
healing [14,15], increased oxidative stress [15-18], pro-
coagulant activity [19,20], and endothelial dysfunction
[21,22]. Several retrospective studies have demonstrated
that hyperglycemia is associated with adverse medical239
240 Biol Blood Marrow Transplant 17:239-248, 2011J. Pidala et al.outcomes including postoperative infections, as well as
mortality after adjusting for the severity of illness in
several conditions [23-31]. In addition, randomized con-
trolled trials examining intensive strategies for glycemic
control have demonstrated a significant mortality be-
nefit for stringent glycemic control both in the setting
of diabetic postmyocardial infarction [32], as well as in
critically ill surgical patients [33]. In a randomized trial
of critically illmedicalpatients, intensiveglycemiccontrol
reduced morbidity including renal injury, time on me-
chanical ventilation, and length of intensive care unit
(ICU) stay; in those with an ICU stay greater than
3 days, in hospital mortality was significantly improved
[34]. Thus, there is a robust literature on the impact of
hyperglycemia onmedical outcomes in several other con-
ditions. Clinical data also supports an adverse effect of
both hypoglycemia and increased glucose variability in
allied investigation [35-39].
Hammer et al. [40] have demonstrated the adverse
impact of aberrant glucose control, encompassinghyper-
and hypoglycemia, as well as glycemic variability within
the first 100 days after HCT on 200 day nonrelapse
mortality (NRM). Although this work demonstrates
the impact of aberrant glucose control on early NRM,
there are several limitations: glucose values were not
obtained beyond day 100 post-HCT; no baseline infor-
mation on preexisting diabetes was available; most
importantly, no information regarding glucocorticoid
therapy was examined, but rather the occurrence of
GVHD was used as a surrogate for glucocorticoid
treatment. Accordingly, the independent effect of glyce-
mic parameters cannot be distinguished from any
adverse effect because of steroid treatment alone, includ-
ing the risk of NRM from immunosuppression and
opportunistic infection. Inaddition, this doesnot address
in particular the common clinical challenge of
glucocorticoid-induced dysglycemia in the treatment of
aGVHD. Accordingly, we have aimed to examine the
independent effect of dysglycemia on outcomes of allo-
geneic HCT recipients treated with glucocorticoids for
aGVHD.METHODS
Patients and Outcome Measures
A series of subjects with biopsy-confirmed
aGVHD treated with glucocorticoids were identified
by retrospective analysis of allogeneic HCT recipients
from 2004 to 2008 at the Moffitt Cancer Center. This
study was approved by the University of South Flori-
da’s institutional review board. The following data
was gathered in all cases, and considered as pre-HCT
variables: diagnosis of diabetes prior to HCT, age,
condition requiring transplantation, Center for Inter-
national Blood and Marrow Transplant Research
(CIBMTR) risk category, remission status at time oftransplant, donor/recipient sex matching, donor rela-
tion, degree of HLA disparity, conditioning regimen
utilized, aGVHD prophylaxis regimen, stem cell
source, CD341 cell dose/kg body weight, and cyto-
megalovirus (CMV) status of donor and recipient. As
well, body mass index (BMI) was calculated for each
subject at time of HCT as weight (kg)/(height in
meters)2. Standard definitions (underweight \18.5,
normal weight 18.5-24.9, overweight 25-29.9, and
obesity 30 and greater) were utilized to categorize indi-
vidual subjects’ BMI. All baseline variables were con-
sidered as covariates in pre-HCTmultivariate models.
For each subject, the following was also collected
and considered as post-HCT variables: maximum
aGVHD grade reached in duration of follow-up [41];
first-line glucocorticoid dose/kg body weight utilized;
the occurrence of refractory aGVHD (defined as ei-
ther grade progression within 3 days from initiation
of glucocorticoids or failure to achieve at least 1 grade
improvement after 5 days of glucocorticoid therapy);
maximum cGVHD grade in duration of follow-up
[42]; and sum of weekly steroid dose in mg/kg of
body weight. In cases where intravenous methylpred-
nisolone was utilized, the dose was computed as pred-
nisone equivalent. Additionally, summary parameters
(maximum, minimum, average, and standard devia-
tion) were calculated for the glucose data available
for each subject from the date of glucocorticoid initia-
tion until death or last follow-up time. Glucose values
were obtained randomly, rarely fasting, from both the
inpatient and outpatient setting, and do not contain
measurements obtained by patient self monitoring.
Each of these glucose parameters was considered as
post-HCT variables in analyses. As well, treatment
for hyperglycemia (insulin or oral agents) post-HCT
and glycemic control group membership were consid-
ered as post-HCT variables.
The following definitions were utilized to create
hyperglycemia treatment groups: The proportion of
total glucose values for each subject .200 mg/dL
was calculated, and a median value for this proportion
for all subjects in the analysis was determined. A con-
trol group was defined as those who did not receive
any treatment (insulin and/or oral agents) and in
whom the proportion of glucose measurements
.200 was smaller than the median value (0.1136,
range: 0-0.913). The second group (well controlled)
was treated with insulin and/or oral agents and had
a proportion of values .200 less than this median.
The final group (poorly controlled) was treated with
these agents, but had a proportion of values .200
greater than this median.Statistical Methods
Baseline characteristics were summarized using
descriptive statistics including mean, median, and
Biol Blood Marrow Transplant 17:239-248, 2011 241Dysglycemia Following Glucocorticoid Therapy for aGVHDstandard deviation for continuous measures, and
frequencies for categoric variables. Glucose measure-
ments were summarized by the parameters maximum,
minimum, average, and standard deviation. The rela-
tionship between the glucose data (maximum, mini-
mum, average, and standard deviation) and the
presence of preexisting diabetes mellitus was examined
using the Wilcoxon rank-sum test.
The relationship between these related glucose
parameters (maximum, minimum, average, standard
deviation) was examined using Fisher’s exact test.
Each of these parameters was significantly related
with the others. As well, there was a significant rela-
tionship between the hyperglycemia treatment group
(control group, well controlled, poorly controlled),
and each of these glucose parameters by Cochran-
Armitage trend test. There was also a significant
relationship between treatment (receipt of insulin
and/or oral agents) and each of these glucose parame-
ters by Cochran-Armitage trend test. Accordingly,
separate multivariable analyses were considered where
only 1 of the above related variables were entered.
A landmark analysis was performed at 12 weeks
post-HCT. As 26 subjects died prior to this time point,
only 147 of the original 173 subjects contributed data to
the landmark analysis. Overall survival (OS) was
estimated using the Kaplan-Meier method from the
12-week landmark. Survival curves among subgroups
were compared using the log-rank test. Accounting
for competing risk events, the cumulative incidence of
primary disease relapse and NRM was calculated by
the Gray method [43]. For the outcomes of OS, the
relationship between this outcome and all baseline vari-
ableswas examinedfirst employing univariable analysis.
Again, for each of these outcomes, Cox proportional
hazard modeling was employed with baseline variables
as covariates. For cumulative incidence ofNRM, a sub-
distribution hazards regressionmodel by themethod of
Fine [44] andGray [43] was utilized for univariable and
multivariable analysis. Those variables with P-value of
.2 or less in univariable analysis were selected for
construction of themultivariablemodel. The backward
selection procedure with a P-value cutoff of .1 was
utilized. Separate multivariate analyses were conducted
to examine pre- and post-HCT variables as defined
earlier. Given the significant relationships between glu-
cose parameters, hyperglycemia treatment groupmem-
bership, and insulin/oral agent treatment, each of these
variables was considered independent of the others in
separate multivariate models.RESULTS
Characteristics of Prednisone-Treated Cohort
From 327 total allogeneic HCTs performed at the
center between 2004 and 2008, 173 subjects wereidentified by retrospective review to have aGVHD
treated with glucocorticoids. Of these, 147 contrib-
uted data at the 12-week landmark analysis. The
baseline characteristics of these 147 subjects are sum-
marized in Table 1. At a median of 21 days (range:
5-79) post-HCT, glucocorticoid therapy was initiated
for the treatment of aGVHD. The starting prednisone
dose was most commonly (72% of subjects) 1 mg/kg
body weight. The total prednisone exposure was a
median of 3.8 (range: 1.12-15) mg/kg at 4 weeks.
The median duration of glucocorticoid treatment
was 381 days (range: 15-1632).
Glycemic Parameters
All available glucose values from date of glucocor-
ticoid initiation until death or last follow-up were ab-
stracted for each patient, resulting in 13,170 total
values for the original 173 subjects. For the cohort of
147 included in the landmark analysis, this included
11,588 total individual values. There was a median of
61 values (range: 8-405) per patient. For each subject,
maximum, minimum, average, and standard deviation
of glucose values were determined. Summary values
are depicted in Figure 1.
Seven patients in this series had preexisting type II
diabetes mellitus prior to HCT; 5 were treated with
oral hypoglycemic agents, and 2 also required insulin
therapy. Those patients with baseline diabetes had
greater maximum (median 460 versus 287 mg/dL,
P 5 .006), average (median 227 versus 145 mg/dL,
P #.001), and standard deviation glucose values (me-
dian 76 versus 47 mg/dL, P 5 .01) than nondiabetics.
OS
With a median follow-up of time of 20 months
(range: 3-55), median OS from initiation of glucocor-
ticoid therapy was 33.7 months (95% confidence inter-
val [CI] 16.4dnot reached). Univariate analyses
examining the relationship between glucose parame-
ters as well as glucose treatment groups (control
group, well controlled, and poorly controlled) are rep-
resented in Figure 2. All of the posttransplant glycemic
parameters significantly predicted OS in separate mul-
tivariate analyses (Table 2). Maximum glucose, aver-
age glucose, and standard deviation of glucose values
demonstrated a linear relationship, with increasing
hazard for death for stepwise increase in these vari-
ables. Minimum glucose level demonstrated a nonlin-
ear relationship, wherein there was an increased hazard
for death in both the 0-60 mg/dL and 81-150 mg/dL
ranges in comparison to a reference of 61-80 mg/dL.
Of patients without baseline diabetes pre-HCT, those
who received treatment with insulin or oral agents suf-
fered an increased hazard for death. As previously de-
fined, hyperglycemia treatment group was also
significantly associated with poor OS: in comparison
Table 1. Baseline Characteristics of Allogeneic HCT
Recipients
Age in years (median, range) 49 (23-69)
Disease
AA 3
ALL 12
AML 63
CLL 8
CML 11
HD 2
MDS/MPD 31
MM 6
NHL 11
Remission status
Active disease 45
Complete remission 70
Primary induction failure 15
Relapsed disease 16
Recipient/donor sex
F/F 30
F/M 35
M/F 34
M/M 45
Recipient/donor CMV serostatus
Neg/Neg 35
Neg/Pos 14
Pos/Neg 55
Pos/Pos 42
HLA matching
Matched sibling 62
Matched unrelated donor 68
Mismatched unrelated donor 17
Conditioning regimen
Busulfan/Cytoxan 1
Busulfan/Fludarabine 143
Fludarabine/Melphalan 2
Fludarabine/TBI 1
Stem cell source
Peripheral blood 147
Bone marrow 0
aGVHD prophylaxis
tacrolimus/methotrexate 108
tacrolimus/mycophenolate mofetil 39
ATG (for mismatched unrelated donors)
Yes 13
No 4
Rituxan
Yes 8
No 138
Max grade overall aGVHD
I 20
II 101
III-IV 26
Refractory aGVHD
Yes 37
No 109
Max grade cGVHD
None or mild 60
Moderate or severe 87
Preexisting diagnosis of diabetes mellitus
Yes 7
No 139
Starting dose of glucocorticoids (per kg body weight)
<1 mg/kg 11
1 mg/kg 105
>1 mg/kg 30
AA indicates aplastic anemia; ALL, acute lymphoblastic leukemia; AML,
acute myelogenous leukemia; CLL, chronic lymphocytic leukemia;
CML, chronic myelogenous leukemia; HD, Hodgkin lymphoma; MDS/
MPD, myelodysplastic syndrome/myeloproliferative disorder; MM, mul-
tiple myeloma; NHL, non-Hodgkin lymphoma; active disease, composite
of CML progressive on tyrosine kinase inhibitor therapy, MDS/MPD, and
severe AA refractory to immunosuppressive therapy; complete
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Figure 1. Box and whisker plot demonstrating summary statistics for
each glycemic parameter. A total of 147 patients contributed data to
the landmark analysis.
242 Biol Blood Marrow Transplant 17:239-248, 2011J. Pidala et al.to the control group, those treated with insulin/oral
agents, and particularly those with poorly controlled
hyperglycemia despite this treatment suffered in-
creased hazard for death. The sum of steroid exposure
did not remain a significant predictor of OS on multi-
variate modeling. As well, BMI was not a significant
predictor of OS. The maximal severity of cGVHD,
as well as the occurrence of glucocorticoid-refractory
aGVHD remained independent predictors of OS in
the post-HCT multivariate model, and thus the
impact of the mentioned glycemic parameters and
hyperglycemia treatment variables were adjusted by
cGVHD and refractory aGVHD.NRM
All glucose parameters demonstrated significant
relationships with the cumulative incidence of NRM
on univariate analysis (Figure 3). In separate multivar-
iate analyses, stepwise increases inmaxium and average
glucose were associated with increased hazard for
NRM. Those with minimum values of 0-60 suffered
increased NRM compared to the reference range of
61-80. Those treated with insulin or oral agents suf-
fered significantly increasedNRM. Finally, in compar-
ison to the control group, those treated with insulin
and/or oral agents with poor glycemic control suffered
significantly greater NRM (Table 3). The impact of
these variables was adjusted by refractory aGVHD,
which remained a significant predictor of NRM in
the multivariate model.remission, complete remission after chemotherapy; primary induction
failure, failure to achieve complete remission after induction chemother-
apy; relapsed disease, recurrent disease after achievement of complete
remission; F, female; M, male; Neg, negative serology; Pos, positive serol-
ogy; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-
versus-host disease; ATG, antithymocyte globulin; HCT, hematopoietic
cell transplantation; CMV, cytomegalovirus.
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Figure 2. (A) Overall survival stratified by maximum glucose (log rank P\.0001). (B) Overall survival stratified byminimum glucose (log rank P\.0003).
(C) Overall survival stratified by mean glucose (log rank P\.0001). (D) Overall survival stratified by standard deviation of glucose (log rank P\.0001).
(E) Overall survival stratified by treatment groups (control, treated with proportion\ median, and treated with proportion . median) (log rank
P\.0001).
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Table 2. Impact of Post-HCT Glycemic Parameters on Overall Survival in Multivariate Analyses*
Multivariable Analysis
95% CI
Model P-Value HR Lower Upper
1. Max glucose level (mg/dL)
101-200 Reference
201-300 .7107 1.197 0.464 3.088
301-400 .0107 3.349 1.324 8.47
>400 .0057 3.626 1.456 9.03
2. Min glucose level (mg/dL)
0-60 .0146 2.103 1.158 3.818
61-80 Reference
81-150 .7272 1.109 0.619 1.987
3. Average glucose level (mg/dL)
85-150 Reference
151-200 .0019 2.303 1.362 3.895
>200 .0557 1.969 0.984 3.941
4. Standard deviation of glucose level (mg/dL)
0-35 Reference
36-60 .2048 1.503 0.801 2.822
>60 .0002 3.211 1.731 5.957
5. Insulin or oral hypoglycemic agent
No Reference
Yes <.0001 3.092 1.755 5.447
6. Groups
1. Control group Reference
2. Treated but < median (well controlled) .0778 2.1 0.921 4.79
3. Proportion > median (poorly controlled) .0010 2.892 1.535 5.448
CI indicates confidence interval; HCT, hematopoietic cell transplantation; HR, hazard ratio.
Separate multivariate models were constructed for each glycemic parameter (minimum, maximum, average, and standard deviation) as well as for
glycemic control group membership and according to hyperglycemic treatment.
*Univariate analysis was conducted for pre-HCT (cytogenetic risk, sexmatching, donor relation, cytomegalovirus [CMV] serostatus matching, remission
status, acute graft-versus-host [aGVHD] prophylaxis regimen, baseline diabetes, body mass index [BMI], age, and CD34+ count), and post-HCT (max-
imal aGVHD grade, maximal cGVHD grade, initial dose of glucocorticoids, occurrence of refractory aGVHD, sum of steroid exposure, maximum, min-
imum, average, and standard deviation of glucose values, glycemic control groupmembership, and hyperglycemia treatment) variables. Thosewith P value
#.2 were included for construction of the multivariable model. The impact of glycemic parameters on overall survival were adjusted by max cGVHD
grade and refractory GVHD. The sum of steroid exposure was incorporated in the multivariate model, but removed in the backward selection
procedure.
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In the management of both aGVHD and cGVHD
after allogeneic HCT, patients are commonly exposed
toaprolongeddurationof therapywithhigh-dosegluco-
corticoids. Many complications and late effects of this
therapy have been well described [6-10]. The problem
of aberrant glucose control with glucocorticoid therapy
after HCT, however, remains inadequately examined
despite its common occurrence in clinical practice.
Basic investigation has demonstrated the adverse im-
pact of hyperglycemia on several vital physiologic
functions, and clinical data from allied disciplines have
demonstrated the adverse impact of hyperglycemia, as
well as both hypoglycemia and glycemic variability on
disease outcomes. Accordingly, we aimed to investigate
the independent prognostic impact of glycemic control
on outcome in a series of patients with aGVHD
treated with glucocorticoids after HCT.
In this series of HCT recipients treated with gluco-
corticoids for aGVHD,we have examined the impact of
glycemic control onOSandNRMin several ways. First,
we have examined the impact of individual glycemicparameters that summarize the glucose data for each
patient. These analyses demonstrate the adverse impact
of each: first, multivariate modeling confirmed an
independent adverse impact of stepwise increases in
maximum glucose on both OS and NRM. Strikingly,
those with a maximum glucose of .400 mg/dL had an
independent hazard for nonrelapse death .9 times
that of the reference group of 101-200 mg/dL. The
directionality of this effect is also in keeping with that
reported by Hammer et al. [40], but the magnitude of
the effecthere is evengreater; inmultivariate analysis ac-
counting for the covariates of severity of disease, patient
age at HCT, type of donor, year of HCT, and presence
of grades II-IV aGVHD, the hazard ratio (HR) for
NRM in the group with maximum glucose values
.300 in that studywas 2.78. Aswell, step-wise increases
in average glucose conferred an increased hazard in
multivariate models of NRM and OS. These findings
are in keepingwith the adverse impact of hyperglycemia
documented inmedical and surgical outcome data from
allied investigations [25-27,30,31]. Similarly, multi-
variate modeling has confirmed the independent
adverse impact of increased glucose variability, here
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Figure 3. (A) NRM stratified by maximum glucose value (P 5 .005). (B) NRM stratified by minimum glucose value (P 5 .002). (C) NRM stratified by
average glucose value (P5 .0003). (D) NRM stratified by standard deviation of glucose values (P5 .007). (E) NRM stratified by treatment group versus
control (P 5 .003).
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Table 3. Impact of Post-HCTGlycemic Parameters on the Cumulative Incidence of NonrelapseMortality inMultivariate analyses*
Multivariable Analysis
95% CI
Model P-Value HR Lower Upper
1. Max glucose level (mg/dL)
101-200 Reference
201-300 .29 3.1 0.38 25.54
301-400 .042 8.82 1.09 71.61
>400 .043 9.15 1.07 78.24
2. Min glucose level (mg/dL)
0-60 .026 2.23 1.1 4.49
61-80 Reference
81-150 .37 0.58 0.18 1.89
3. Average glucose level (mg/dL)
85-150 Reference
151-200 <.001 3.82 1.94 7.51
>200 .9 0.91 0.22 3.74
4. Standard deviation of glucose level (mg/dL)
0-35 Reference
36-60 .48 1.44 0.53 3.94
>60 .07 2.59 0.94 7.13
5. Insulin or oral hypoglycemic agent
No Reference
Yes .005 4.64 1.6 13.47
6. Groups
1. Control group Reference
2. Treated but <median (well controlled) .2 2.24 0.65 7.77
3. Proportion > median (poorly controlled) .036 3.67 1.09 12.37
CI indicates confidence interval; HR, hazard ratio.
Separate multivariable models were constructed for each glycemic parameter (minimum, maximum, average, and standard deviation) as well as for gly-
cemic control group membership and according to hyperglycemia treatment.
*Univariate analysis was conducted for pre-hematopoietic cell transplantation (pre-HCT; cytogenetic risk, sex matching, donor relation, cytomegalo-
virus [CMV] serostatus matching, remission status, acute graft-versus-host disease [aGVHD] prophylaxis regimen, baseline diabetes, age, and CD34+
count) and post-HCT (maximal aGVHD grade, maximal cGVHD grade, initial dose of glucocorticoids, occurrence of refractory aGVHD, sum of steroid
exposure, maximum, minimum, average, and standard deviation of glucose values, glycemic control group membership, and hyperglycemia treatment)
variables. Those with value#.2 were included for construction of the multivariable model. The impact of glycemic parameters on nonrelapse mortality
(NRM) was adjusted by refractory aGVHD. The sum of steroid exposure was included in the multivariate model, but was removed in the backward
selection procedure.
246 Biol Blood Marrow Transplant 17:239-248, 2011J. Pidala et al.represented by the standard deviation of glucose values,
on OS. Finally, those with minimum glucose values
below the reference range suffered a significantly
worse OS and NRM.
In addition to examining the impact of individual
summary glucose parameters on OS and NRM, we
have also here examined the association between hyper-
glycemia treatment and its success and these outcomes.
Of those without baseline diabetes, treatment with
insulin or oral agents post-HCT was associated with
significantly worsened OS and NRM. Importantly,
this therapy was significantly related to the earlier
mentioned glycemic parameters; treatment with these
agents was strongly dependent upon the degree of
hyperglycemia. Therefore, the effect observed likely
reflects the associated severity of hyperglycemia. As
well, we have examined the impact of poor glycemic
control among those who have received treatment for
hyperglycemia. Compared to the reference no treat-
ment group, those who had poor glycemic control de-
spite such therapyddefined by sustained values .200
mg/dLdsuffered significantlyworsenedOSandNRM.These findings demonstrate the adverse associa-
tion of dysglycemia with OS and NRM in the setting
of glucocorticoid therapy for aGVHD. This data com-
plements that of Hammer et al. [40], but offers novel
information in the following ways: First, patients stud-
ied here differ in that they include exclusively those
with aGVHD treated with glucocorticoids. Second,
glucose values were obtained for each subject from
the onset of glucocorticoid therapy until the last con-
tact or death; glucose values were only obtained to
day 100 as a predictor of 200 day NRM in the former
study. In addition, we have demonstrated here that
those with baseline diabetes mellitus had significantly
greater maximum and average glucose values, as well
as variation in serum glucose values, thereby identify-
ing an especially high risk group.Next, we have impor-
tantly demonstrated the adverse effect of the studied
glycemic parameters, independent from the adverse
impact of glucocorticoid therapy. We have also dem-
onstrated that poor glycemic control despite insulin
or oral agent therapy is associated with worse outcome.
Finally, we have confirmed the adverse impact of these
Biol Blood Marrow Transplant 17:239-248, 2011 247Dysglycemia Following Glucocorticoid Therapy for aGVHDglycemic parameters on NRM, but also have for the
first time shown a robust association with OS.
As these data demonstrate an adverse association
between dysglycemia incurred in the setting of gluco-
corticoid therapy for aGVHD and outcomes, efforts
to limit this burden are of importance. In regard to the
management of dysglycemia, the data here suggest the
following: first, these findings support the importance
of routine assessment of glycemic control and its requi-
site management. This is likely best achieved in the set-
ting of a multidisciplinary team, for example, including
a transplant physician, nurse, nutritionist, and endocri-
nologist, to address the patient’s diet, activity, glycemic
control, and the associated therapy.Thosewith baseline
diabetes constitute an especially vulnerable group that
requires particular attention. Next, the data suggest
potential targets in the management of this complica-
tion: Asminimumvalues below60mg/dLare associated
with both worsened OS and increased NRM, these low
values should be minimized. Accordingly, a major goal
of therapy should be to restrict severe low values in the
management of hyperglycemia. Next, as maximum
values .200 are associated with worsened OS and
NRM, a goal of therapy should be to limit maximum
values to below 200 as possible. Finally, data demon-
strating the adverse impact of increased glucose variabil-
ity suggest that minimizing this variation should be
another therapeutic goal. The optimal agents (eg, oral
hypoglycemic drugs, insulin therapy) and schedule to
achieve this control, avoid hypoglycemia, and reduce
variability remain to be determined. As well, this retro-
spective analysis has demonstrated the independent
association of glycemic parameters and hyperglycemia
treatment group membership with the outcomes of
OS and NRM; however, definitive conclusions regard-
ing optimal glycemic control in this setting would
require an adequately powered prospective randomized
trial examining a strict glycemic control strategy.
Finally, efforts at more stringent glycemic control
are reactive in nature: efforts toward ameliorating the
underlying problem, namely, more effective aGVHD
prevention, primary therapy, avoidanceofglucocorticoid-
refractory aGVHD, as well as investigation into nonglu-
cocorticoid or glucocorticoid-sparing approaches, may
help limit these adverse effects of glucocorticoids.ACKNOWLEDGMENTS
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